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The genetic cause of some familial nonsyndromic renal cell carcinomas (RCC) defined by at least two affected first-degree relatives is
unknown. By combining whole-exome sequencing and tumor profiling in a family prone to cases of RCC, we identified a germline
BAP1 mutation c.277A>G (p.Thr93Ala) as the probable genetic basis of RCC predisposition. This mutation segregated with all four
RCC-affected relatives. Furthermore, BAP1 was found to be inactivated in RCC-affected individuals from this family. No BAP1mutations
were identified in 32 familial cases presenting with only RCC. We then screened for germline BAP1 deleterious mutations in familial
aggregations of cancers within the spectrum of the recently described BAP1-associated tumor predisposition syndrome, including uveal
melanoma, malignant pleural mesothelioma, and cutaneous melanoma. Among the 11 families that included individuals identified as
carrying germline deleterious BAP1 mutations, 6 families presented with 9 RCC-affected individuals, demonstrating a significantly
increased risk for RCC. This strongly argues that RCC belongs to the BAP1 syndrome and that BAP1 is a RCC-predisposition gene.Renal cell carcinoma (RCC [MIM 144700]) represents ~2%
of all malignant diseases in adults.1 Although most cases
are sporadic, approximately 2% to 4% of RCC cases are
hereditary. The majority of familial RCC is linked to
monoallelic VHL (MIM 608537) mutations and is
associated with the von Hippel Lindau syndrome (VHL
[MIM 193300]). Other cases are linked to FLCN (MIM
607273) mutations defining the Birt-Hogg-Dube´ (BHD
[MIM 135150]) syndrome, to monoallelic MET (MIM
164860), FH (MIM 136850), SDHB (MIM 185470), or
CDC73 (MIM 607393) mutations, or to chromosome 3
translocations.2,3 However, the hereditary origin of some
familial nonsyndromic RCC cases, defined by at least two
affected first-degree relatives, remains unknown. The best
genetic model to date is an autosomal-dominant inheri-
tance according to a large European segregation study,
which gathered 60 families with members who tested
negative for VHL germline mutations.4 By combining
whole-exome sequencing, genotyping, and tumor
profiling in a family with RCC-prone individuals, we iden-1Institut Curie, Inserm U830, Paris 75248, France; 2Ge´ne´tique Oncologique EP
France and Centre Expert National Cancers Rares PREDIR, INCa/AP-HP, Hoˆp
Biology, Institut Curie, Paris 75248, France; 4De´partement de Chirurgie, Institu
c¸age, Evry 91057, France; 6Unite´ Mixte de Ge´ne´tique Constitutionnelle des Ca
rard, and INSERM U1052, CNRS UMR5286, Universite´ Lyon 1, Centre de Rech
U900, Paris 75248, France; 8Service d’Oncologie, Centre Hospitalier G. Renon
69622, and Centre Le´on Be´rard, Lyon 69008, France; 10Laboratoire de Diagnost
coge´ne´tique, Institut Jean Godinot, Reims 51056, France; 12Service de Dermato
13Mines ParisTech, Fontainebleau 77300, France; 14Service de Ge´ne´tique, Ins
U946, Paris 75010, France; 15Department of Medicine, Institut de Cance´rologie
pital, APHP, Paris 75018, and Inserm U976, Skin Research Center, Saint Louis H
Paris 75270, France
18These authors contributed equally to this work
*Correspondence: marc-henri.stern@curie.fr
http://dx.doi.org/10.1016/j.ajhg.2013.04.012. 2013 by The American Societ
974 The American Journal of Human Genetics 92, 974–980, June 6, 2tified a BAP1 (MIM 603089) mutation as the genetic basis
for RCC predisposition. Predisposition to RCC was further
confirmed in independent families withmembers who car-
ried deleterious BAP1 mutations.
Aiming at identifying new genetic factors of familial
RCC, we characterized a two-generation family with a
high incidence of RCC. All procedures followed were in
accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) and proper informed consents were obtained.
Family A included individuals with multiple cancer types,
including four first-degree relatives over two generations
with RCC (Figure 1A). This number of RCCs within a
non-VHL family is uncommon and indicates a genetic pre-
disposition. As a comparison, only 3 out of the 60 non-
VHL RCC-affected families reported by Woodward et al.
had asmany affected individuals.4 The index case of family
A (III-1) developed multiple and bilateral clear cell RCCs
(ccRCC) at 37, 39, and 47 years of age as well as two inde-
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Figure 1. Clinical and Biological Character-
ization of Family A
(A) Pedigree and tumor spectrum of family A.
Proven BAP1 mutation carriers are indicated
with a red plus sign, obligate mutation carriers
with a black plus sign, and proven wild-type in-
dividuals with a black minus sign. Abbrevia-
tions are as follows: RCC, renal cell carcinoma;
Breast, breast carcinoma. Other cancers: I-1,
esophagus carcinoma; II-6, head and neck carci-
noma; II-7, esophagus carcinoma; III-1, cervix
carcinoma; III-7, lung carcinoma; III-9, adeno-
carcinoma of unknown primitive tumor
(ACUP).
(B) Whole-genome tumor analysis by SNP array
identified 3p21-containing BAP1 gene as the
unique region of consistent loss of heterozygos-
ity (LOH) and identical by descent (IBD) haplo-
type. The three lower tracks correspond to the
three tumors analyzed in Affymetrix SNP6.0,
using the number of consecutive probesets as
coordinates. LOH is indicated by red boxes
(IBD haplotype retained in the tumor) and
black boxes (unshared haplotype retained in
the tumor). Cumulative LOH is shown on the
upper track with the location of BAP1. IBD is
defined between III-1, III-3, and III-5 affected
individuals.
(C) BAP1 transcript detected in index case III-1.
Three sequences are visible on the electrophe-
rogram: the wild-type cDNA, the cDNA with
the missense c.277A>G mutation, and the
abnormally spliced cDNA as a consequence
of the new acceptor splicing site within exon
5. The alternative splicing is illustrated below
the electropherogram. The cDNA sequence
was amplified from a lymphoblastoid cell line
derived from patient III-1.
(D) Immunohistochemistry from a renal cell
carcinoma affecting index case III-1. The left
panel shows adjacent normal renal tissue
of the tumor sample. The brown staining illus-
trates a significant normal nuclear immune-
labeling of BAP1 protein. The right panel
shows a subset of tumor cells with a blue coun-
terstaining indicating a lack of BAP1 expression
in tumors.negative for germline VHL and FLCN mutations, chromo-
some 3 translocations, and BRCA1 (MIM 113705), BRCA2
(MIM 600185), and TP53 (MIM 191170) alterations. Her
father (II-2), cousin (III-5), and aunt (II-5) developed
RCC, and for two of them at early onset (40 and 47 years
of age for III-5 and II-2, respectively). Other tumor types
were reported in this family: breast carcinomas at early
onset in three female individuals (III-1, III-3, and III-11),
including the previously mentioned bilateral breast
carcinoma for the index case; a pericardial metastatic
adenocarcinoma of unknown primary origin (III-9); and
a lung carcinoma (III-7) (Figure 1A).
Whole-exome sequencing of germline DNA was per-
formed for III-1 and her first-degree cousin (III-5), both
affected with RCC. After liquid capture enrichment of
coding sequences (SureSelect kit V1, Agilent) and
sequencing performed on the SOLiD platform (v.4),
approximately 100 million uniquely mapped reads wereThe Amobtained for each case (alignment performed on Bioscope
Aligner, UCSC genome version hg19, February 2009,
Genome Reference Consortium GRCh37). SAMtools
pileup was utilized to enumerate variations.5 Approxi-
mately 90% of exons were covered at least 13, and the
median coverage was 603. Detected variation was anno-
tated with ANNOVAR with the SeattleSeq Annotation
tool.6 Seven unknown (absent in dbSNP v.137) nonsynon-
ymous single-nucleotide variations (SNVs) at the hetero-
zygous state, and shared between the two individuals,
were detected. A summary of the sequencing results is pre-
sented in Tables S1 and S2 (available online). Five SNVs
were predicted by the PolyPhen method to have high
deleterious impacts on their corresponding protein func-
tion.7 Three of these were validated by Sanger sequencing
(Table 1). A single deletion, leading to a frameshift, was
also detected but was not considered as a possible candi-
date (Table S3).erican Journal of Human Genetics 92, 974–980, June 6, 2013 975
Table 1. SNVs with Predicted Damaging Effect on the Protein Function
Gene Chr Positiona Accession NCBI Ref/Alt Alt Transcript Alt Protein LOH in RCC IBD Coverage Alt Freq
BAP1 3 52442072 NM_004656.2 T/C c.A277G p.Thr93Ala 1 1 39 0.21
KALRNb 3 124397063 NM_001024660.3,
NM_007064.3
G/A c.G7220A p.Arg2407His 0 1 35 0.4
ERCC5b 13 103519045 NM_000123.3 G/A c.G2383A p.Ala795Thr 0 1 48 0.48
Mutation nomenclature follows the recommended guidelines of the Human Genome Variation Society with the nucleotide numbering based on GenBank refer-
ence sequence indicated by its accession NCBI number. Nucleotide numbering denotes the adenosine of the annotated translation start codon as nucleotide po-
sition þ1. Only Sanger-validated SNVs are indicated in this table. Abbreviations and definitions are as follows: Alt freq, ratio of alternative/total reads; Alt protein,
alternative protein; Alt transcript, alternative transcript; Chr, chromosome; Coverage, number of independent reads; IBD, identical by descent region; LOH in RCC,
loss of heterozygosity in renal cell carcinoma of individual III-1 from family A; Ref/Alt, reference and alternative alleles; SNVs, single-nucleotide variants.
aPosition refers to the chromosome version hg19/GRCh37.
bThis variation potentially impacts several alternative transcripts.To further evaluate these variants as candidate predispo-
sition genes, the genomic profiles of tumors from family A
were analyzed by SNP arrays (Affymetrix SNP6.0). If the
predisposition gene responsible for RCC in this family fol-
lows the Knudson’s two-hit model for tumor suppressor
genes, one can assume that (1) one allele is inactivated
by a germline deleterious mutation, (2) this mutated allele
is retained in the tumor, and (3) the other allele is inacti-
vated somatically, classically by deletion. The available
RCC sample from the index case showed loss of heterozy-
gosity (LOH) for the 3pter–14.1 chromosomal region
(genomic position 0–64 Mb) as the unique acquired large
genomic alteration in this tumor (Figure 1B).
Germline SNP-array genotyping of ten members from
the family A was also performed. The list of identical by
descent (IBD) regions for the two cousins (III-1 and III-5)
included 3p21.31–13 (genomic positions 46–72 Mb), and
this was confirmed by whole-exome sequencing (Table
S4). The shared haplotype in the 3p chromosomal region
retained in the tumor narrowed the candidate region to
3p21.31–14.1 (46–64 Mb) (Figures 1B and S1).
Because the dbSNP v.137 database contains some SNPs
with pathologic consequences, we detected six variants
with predicted high impact on protein function, reported
in dbSNP v.137 with low or unknown minor allele fre-
quencies (MAF), andcommonbetween III-1 and III-5. These
variantswere not further considered because nonewere in a
LOH region in the RCC from the III-1 index case (Table S5).
We then evaluated the three validated unknown SNVs
with potential deleterious effects. All three SNVs seg-
regated with RCC-affected relatives, but only the
g.52442072T>C substitution in BAP1 (BRCA1 Associated
Protein 1) was located in the 3p LOH region. This BAP1
SNV was confirmed by Sanger sequencing in all RCC-
affected relatives with available DNA (Figures 1A and S2).
Because the 3p21 haplotype encompassing the BAP1 mu-
tation was shared by the two cousins, the father (II-2)
and aunt (II-5) of the index case were obligate mutation
carriers, indicating a complete cosegregation of the BAP1
mutation with RCC in this family.
BAP1 encodes a nuclear ubiquitin carboxyterminal hy-
drolase (UCH), which was initially described as binding976 The American Journal of Human Genetics 92, 974–980, June 6, 2to the BRCA1 RING finger and enhancing BRCA1-medi-
ated cell growth suppression.8 BAP1 interacts with ASXL1
(MIM 612990) to form the Polycomb group Repressive
Deubiquitinase complex (PR-DUB). This complex deubi-
quitinates H2A and participates in HOX repression by
chromatin modification.9 BAP1 also contains a UCH37-
like domain (ULD), which is the binding site for the tran-
scriptional factor HCFC1 (MIM 300019). The HCFC1/
BAP1 complex contributes to cell cycle progression and
BAP1 deubiquitinating activity is probably involved in
HCFC1 turnover.10 BAP1 was found to be frequently
somatically inactivated in uveal melanoma and mesotheli-
oma, and germline mutations predispose to these tu-
mors.11–14 More recently, BAP1 was found somatically in-
activated in 8% to 14% of ccRCCs.15,16 Deleterious
mutations found in BAP1 in various pathological cases
are mainly leading to truncated BAP1 proteins, by
nonsense mutations, frameshifts, or splicing defects.17
The BAP1 mutation detected in family A created a new
splicing acceptor site within exon 5, with functional conse-
quences demonstrated by transcript analyses from a lym-
phoblastoid cell line derived from the index case. Two tran-
scripts resulting from this mutation were detected:
c.256_277del (p.Ile87MetfsX4) andc.277A>G(p.Thr93Ala)
(Figure 1C). Quantitative cDNA characterization and Exon-
Trap approach (MoBiTec; Figure S3) indicated that 80% of
BAP1 transcripts corresponded to the aberrantly spliced
transcripts leading to a frameshift, whereas less than 20%
corresponded to the missense mutation. Furthermore, the
location of this missense mutation close to the active site
of the UCH domain, and the amino acid phylogenetic con-
servation, strongly suggest that the p.Thr93Ala amino acid
substitution impairs BAP1 deubiquitinating activity.18
Finally, BAP1 was undetected by immunohistochemistry
(IHC, sc-28383 antibody from Santa Cruz Biotechnology)
in three available RCCs from this family, two from III-1
and one from II-2 (Figure 1D). The monoallelic BAP1 germ-
line deleterious mutation and the absence of detectable
BAP1 in renal tumors in family A, togetherwith the demon-
strated role of BAP1 in nonhereditary RCCmalignancy,15,16
strongly argue that theBAP1mutation is the genetic basis of
renal cancer predisposition in this family.013
Figure 2. Pedigree of the Families with
Members Carrying BAP1 Mutations
(A) Venn diagram of familial tumor spec-
trum of the 60 families screened for BAP1
germline mutation. Numbers in black
represent number of families with mem-
bers carrying a given tumor association,
and numbers in red represent number of
these families with members carrying
BAP1 mutation.
(B) Pedigrees of families withmembers car-
rying a germline BAP1 mutation. Arrows
indicate index cases. Proven BAP1 muta-
tion carriers are indicated with a red plus
sign, obligate mutation carriers indicated
with a black plus sign, and proven wild-
type individuals indicated with a black
minus sign.
Abbreviations are as follows: CM, cuta-
neous melanoma; MPM, malignant
pleural mesothelioma; UM, uveal mela-
noma.To further evaluate the contribution of germline BAP1
mutations in RCC susceptibility, two series of individuals
were screened. The first series included 32 unrelated
French RCC individuals with at least one first- or second-
degree relative affected with RCC and who tested negative
for RCC-predisposing genes (Table S6). Half of this series
was previously published for the French cases.4 Screening
was performed by the sensitive heteroduplex detection
method EMMA, which allows the detection of both small
size mutations and large gene rearrangements.19 The
EMMA amplicons, having an abnormal profile, were
Sanger sequenced (Table S7). No BAP1 mutation was de-
tected in this series, suggesting that germline BAP1 muta-
tions rarely explain families affected only with RCC.The American Journal of HumaFollowing the already described
spectrum of diseases associated with
BAP1 mutations (MIM 614327), an
additional series of familial cases was
considered in order to evaluate the
occurrence of RCC in families with
members carrying BAP1mutations. A
cohort of 60 European index cases,
with familial features suggesting a
high riskofBAP1mutationas agenetic
basis of cancer, was assembled from
three reference cancer centers in the
Paris area. All included familial cases
affected either with uveal melanoma
(UM), cutaneous melanoma (CM), or
mesothelioma (MPM) that had at least
one first- or second-degree relative
affected with one of these malig-
nancies (Figure 2A; Table S8). It should
be noted that families with only CM
were not included and that RCC was
not a selection criteria for screeningthese families. Germline deleterious BAP1 mutations were
identified in 11 out the 60 families (18%), especially in all
families presenting bothUMandMPM (5 out of 5), whereas
families with onlyUMorwith bothUMandCMwere rarely
mutated (1/8 and 3/42, respectively) (Table 2, Figures 2A
and 2B). All identified mutations led to a premature stop
codon (nonsense, frameshift, or splicing mutations). Clin-
ical records for these 11 families comprised 83 individuals
(38 females, 45males, 2 unknown; Table S9)with2 to14 rel-
atives available per family in 1 to 3 generations (average age
54.0 [18–90], 1withunknownage). A total of 33 individuals
were diagnosed with UM, MPM, or CM in diverse associa-
tions; 14 individuals had other cancers, including renal,
lung, breast, prostatic, thyroid, and bladder carcinomas.n Genetics 92, 974–980, June 6, 2013 977
Table 2. Families with Members Carrying BAP1 Mutations
ID
Cancers and Age at Onset in Years
BAP1 Mutation Predicted EffectUM MPM CM RCC
Family B II-1 (35) II-1 (36) c.629dupT (p.Met211HisfsX32) truncating
II-3 (NA) II-2 (54)
I-3 (NA) I-1 (57)
Family C II-5 (52) II-5 (59) I-2 (50) c.1654delG (p.Asp552IlefsX19) truncating
II-6 (53) I-5 (54)
II-4 (41)
Family D III-2 (48) III-2 (34) I-1 (55) c.437þ1G>A (p.?) truncating
II-1 (70)
III-7 (50)
Family E III-1 (44) II-1 (60) c.219delT (p.Asp73GlufsX5) truncating
I-1 (60)
Family F II-1 (41) c.670dupC (p.His224ProfsX19) truncating
I-1 (64)
Family G II-4 (57) I-1 (59) II-1 (49) II-3 (36) c.37þ1delG (p.?) splicinga
II-3 (29,31,34)
Family H I-3 (62) c.1647delT (p.Val550SerfsX21) truncating
I-1 (59)
Family I II-1 (44) I-1 (66) c.1846delG (p.Val616X) truncating
Family J I-1 (53) I-4 (NA) I-2 (45) I-2 (53) c.78_79delGG (p.Val27AlafsX41) truncating
I-3 (33)
Family K II-4 (42) II-2 (38) I-1 (58) II-3 (34) c.66011T>A (p.?) splicing
II-1 (47,52)
II-6 (42)
Family L I-1 (71) II-1 (47) c.588G>A (p.Trp196X) splicing
Mutation nomenclature follows the recommended guidelines of the Human Genome Variation Society with the nucleotide numbering based on GenBank refer-
ence sequence NM_004656.2. Nucleotide numbering denotes the adenosine of the annotated translation start codon as nucleotide position þ1.
aAll splicing mutations had a high probability to impair splicing according to Alamut software.Interestingly, 9 RCCswere reported in 6 of the 11 families
with members carrying BAP1 mutations. Four of these six
RCC-affected families were presenting with both UM and
MPM. Furthermore, RCC was associated with a BAP1-
mutated status in four cases for which the status was
available (all individuals from independent families).
RCC-affected individuals could not be tested in two other
families with members carrying BAP1 mutations with
RCC. Renal cell carcinoma is a relatively rare disease, with
a lifetime risk in the French population estimated to be
0.0056 formenand0.0021 forwomen.20According to these
data, the probability to have 9 RCCs by the age of 90 in 83
individuals from families withmembers carrying BAP1mu-
tations is estimated to be 108 (95% CI: 0.05–0.20) if
applying the larger male probability to the whole cohort.
Taking into account that all individuals with known age
were younger than90years of age and that the 8 individuals
affected by RCC were younger than 60 years of age in these978 The American Journal of Human Genetics 92, 974–980, June 6, 2families with members carrying BAP1 mutations, the low
boundary of RCC relative risk in a BAP1 mutated context
is 8-fold (Table S10). Such an elevated risk of RCC in families
with members carrying BAP1 mutations strongly suggests
that BAP1 is a RCC-predisposition gene. Furthermore, two
individuals with BAP1 germline mutations were previously
reported with RCC.14,21 Considering the recently described
BAP1 cancer syndrome,which includesUM,CM,MPM,and
putatively other cancers,22 our findings indicate that RCC
should be added to the tumor spectrum of this syndrome.
Because somatic BAP1 deleterious mutations have been
associated with high-grade RCCs,16 we evaluated the Fuhr-
man grade of the four paraffin-embedded tumor slides
available. Three RCCs were found to be of grade I-II (family
A) and one of grade III (family B). These few cases did not
allow definitive conclusions but suggested that germline
and somatic BAP1 mutations may have different conse-
quences concerning RCC aggressiveness.013
By using this large cohort of families with members
carrying BAP1mutations, we then evaluated a possible pre-
disposition to other cancers besides RCC. Evidence for
breast cancer predisposition was ambiguous for the
following reasons. Only two breast cancers, including
one at early onset, were reported in seven families with
members carrying BAP1 mutations published so
far.13,14,17,21,23 In the 12 families with members carrying
BAP1 mutations reported here, family A was the only one
providing two mutation carriers with early-onset breast
tumors including a bilateral case, and conversely presented
neither UM, nor MPM nor CM. However, it should be
noted that index case from family A harbors numerous
benign cutaneous naevi. LOH at the BAP1 locus with reten-
tion of the mutated BAP1 allele and loss of BAP1 expres-
sion were demonstrated for family A breast carcinomas
(Figures 1B and S4). However, another second-degree rela-
tive also developed a breast cancer at early onset, although
not carrying the BAP1 mutation. Thus, the overall inci-
dence of breast tumors in families with members carrying
BAP1 mutations was not sufficient to include or exclude
this tumor type in the BAP1 syndrome. We further
screened 187 unrelated individuals with breast cancer pre-
disposition who tested negative for BRCA1 and BRCA2
mutations and we failed to identify germline BAP1 trun-
cating mutations, confirming a previous result on an
independent series of 47 individuals with breast cancer
predisposition.24 Furthermore, somatic BAP1 mutations
are found in less than 1% of breast tumors, not supporting
a major role for BAP1 in breast cancer.25,26
Predisposition for lung cancers has also been suggested
by Abdel-Rahman et al.23 They reported a family with a
BAP1 germline truncating mutation and demonstrated
the loss of the BAP1 normal allele in a lung carcinoma
arising in a mutation carrier. In our study, two BAP1-
mutated index cases were affected with lung carcinomas
before 55 years old without reported history of smoking
(II-1 and I-1 in families G and J, respectively; Figure 2B).
Furthermore, the NCI-H226 non-small-cell lung cancer
cell line is the first known example of BAP1 inactiva-
tion.8 However, somatic mutations of BAP1 were rarely
found in large sequencing studies of lung cancers.27,28
Thus, whether BAP1 mutations predispose to breast or
lung carcinomas still remain to be determined.
Next-generation sequencing technologies revolution-
ized the field of human genetics, enabling fast and cost-
effective generation of genome-scale sequence data
with exquisite resolution and accuracy. Whole-exome
sequencing allowed us to find that a BAP1 mutation was
the genetic basis of RCC predisposition in a tumor-prone
family. By gathering this large cohort of families with
members carrying BAP1mutations, we statistically demon-
strated a link between the predisposition to develop RCC
and BAP1 germline deleterious mutations. The BAP1
syndrome is a rare entity, which makes it difficult to fully
evaluate its clinical spectrum, prevalence in the general
population, and actual predisposing risk for cancers. AThe Amstriking feature is the tumor spectrum heterogeneity
among the growing number of reported families with
members carrying BAP1 mutations. Possible explanations
for this heterogeneity include different consequences of
the various BAP1 mutations, influences of the genetic
background or of environment factors (asbestos exposure),
or biases in selecting individuals for screening. Whether
including RCC in the BAP1-associated tumor spectrum
will modify genetic testing and lead to identification of
familial RCC without other tumor association is yet to be
determined. The next challenge required for the manage-
ment of mutation carriers is to estimate carefully tumor
risks from large epidemiological studies.Supplemental Data
Supplemental Data include four figures and ten tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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